has been cited by the following article(s):
|
[1]
|
Analysis of the trends of polypharmacy and high‐dose prescriptions in Japan
Asia-Pacific Psychiatry,
2022
DOI:10.1111/appy.12488
|
|
|
|
|
[2]
|
NeuroPsychopharmacotherapy
2022
DOI:10.1007/978-3-030-62059-2_22
|
|
|
|
|
[3]
|
NeuroPsychopharmacotherapy
2020
DOI:10.1007/978-3-319-56015-1_22-1
|
|
|
|
|
[4]
|
NeuroPsychopharmacotherapy
2020
DOI:10.1007/978-3-319-56015-1_22-1
|
|
|
|
|
[5]
|
NeuroPsychopharmacotherapy
2020
DOI:10.1007/978-3-319-56015-1_22-1
|
|
|
|
|
[6]
|
Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan
Australian & New Zealand Journal of Psychiatry,
2018
DOI:10.1177/0004867418805559
|
|
|
|
|
[7]
|
Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method
International Journal of Neuropsychopharmacology,
2015
DOI:10.1093/ijnp/pyu016
|
|
|
|
|
[8]
|
Antipsychotic Medication and Risk of QTc Prolongation: Focus on Multiple Medication and Role of Cytochrome P450 Isoforms
Open Journal of Psychiatry,
2014
DOI:10.4236/ojpsych.2014.44044
|
|
|
|